Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the field caused by the FDA Modernization Act 2.0, 2023 has set an exciting precedent for the upcoming year. However, the translation rates of oncology therapeutics into the clinic remain at 20%, proving there remains a large unmet need for tools to support drug development efforts in a patient-specific context at the preclinical and early translational levels.

Time: 09:00 – 17:00

Venue details: Grand Hyatt At SFO, 55 South Mcdonnell Road, San Francisco, California, 94128, United States

Price:
Free: USD 0.00

Speakers: Alba Gonzalez-Junca – Associate Director – Arsenal Biosciences, Aldo Pourchet – Chief Executive Officer and Co-Founder – Omios Biologics, Alina Ainbinder – Principal Scientist – Takeda, and more.